Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502.
Daniel G StoverRoberto SalgadoOleksander SavenkovKarla BallmanErica L MayerMark Jesus M MagbanuaSherene LoiMark VaterKristyn GloverMark WatsonYujia WenWilliam Fraser SymmansCharles M PerouLisa Anne CareyAnn H PartridgeHope S RugoPublished in: NPJ breast cancer (2024)
Association of stromal tumor-infiltrating lymphocytes (sTILs) with survival outcomes among patients with metastatic breast cancer (MBC) remains unclear. The primary objective was to evaluate the association of sTILs with progression-free survival in randomized phase III trial CALGB 40502. sTILs were associated with progression-free and overall survival in chemotherapy-treated MBC when controlling for treatment arm; however, this effect did not remain significant after additional adjustment for hormone receptor status. CALGB is now part of the Alliance for Clinical Trials in Oncology. Trial Registration: ClinicalTrials.gov: NCT00785291.